Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 May 2018Website:
http://scholarrock.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:38:45 GMTDividend
Analysts recommendations
Institutional Ownership
SRRK Latest News
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tu.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the Ame.
Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024.
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Rushmie Nofsinger - Vice President, Investor Relations & Corporate Affairs Jay Backstrom - Chief Executive Officer Mo Qatanani - Head of Research. Ted Myles - Chief Operating Officer & Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Allison Bratzel - Piper Sandler Tessa Romero - JPMorgan Srikripa Devarakonda - Truist Securities Etzer Darout - BMO Capital Markets Andres Maldonado - H.C.Wainwright Ernesto Rodriguez-Dumont - Cowen Rushmie Nofsinger Good morning.
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollment and is expected to report results in Q4 2024. Data from the TOPAZ study showed consistent gains in motor function scores for SMA patients treated with apitegromab. It is expected that the global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032.
Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with a phase 2 proof-of concept trial in 2024. The biopharma company will work toward an investigational new drug (IND) application submission in 2025.
What type of business is Scholar Rock Holding?
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
What sector is Scholar Rock Holding in?
Scholar Rock Holding is in the Healthcare sector
What industry is Scholar Rock Holding in?
Scholar Rock Holding is in the Biotechnology industry
What country is Scholar Rock Holding from?
Scholar Rock Holding is headquartered in United States
When did Scholar Rock Holding go public?
Scholar Rock Holding initial public offering (IPO) was on 25 May 2018
What is Scholar Rock Holding website?
https://scholarrock.com
Is Scholar Rock Holding in the S&P 500?
No, Scholar Rock Holding is not included in the S&P 500 index
Is Scholar Rock Holding in the NASDAQ 100?
No, Scholar Rock Holding is not included in the NASDAQ 100 index
Is Scholar Rock Holding in the Dow Jones?
No, Scholar Rock Holding is not included in the Dow Jones index
When does Scholar Rock Holding report earnings?
The next expected earnings date for Scholar Rock Holding is 09 August 2024